NCT03539094: IFMS

Intermittent Fasting in Multiple Sclerosis

Completed NA Last updated 16 January 2024

What this trial tests

NA trial testing Intermittent fasting in Relapsing Remitting Multiple Sclerosis in 61 participants. Completed in 20 January 2022.

Timeline

1 January 2018

Primary endpoint
20 January 2022

20 January 2022

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	61
Start date	1 January 2018
Primary completion	20 January 2022
Estimated completion	20 January 2022
Sites	1 location across United States

Drugs / interventions tested

• Intermittent fasting

Conditions studied

• Relapsing Remitting Multiple Sclerosis — all drugs for Relapsing Remitting Multiple Sclerosis →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Relapsing Remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled trial that will test the effects of intermittent fasting (IF) in subjects with relapsing-remitting MS (RRMS). The goal of this clinical trial is to acquire objective evidence regarding whether an IF diet has beneficial effects in MS patients.Two dietary regimens, IF and western diet, will be compared in a randomized, controlled, single-blinded 12 week trial in RRMS patients. This is a single-center study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials.
   Schepici G, Silvestro S, Bramanti P, Mazzon E. · · 2019 · cited 123× · PMID 31512505 · DOI 10.1177/0963689719873890
2. Targeting the gut to treat multiple sclerosis.
   Ghezzi L, Cantoni C, Pinget GV, Zhou Y, et al · · 2021 · cited 84× · PMID 34196310 · DOI 10.1172/jci143774
3. Effects of dietary restriction on neuroinflammation in neurodegenerative diseases.
   Fontana L, Ghezzi L, Cross AH, Piccio L. · · 2021 · cited 77× · PMID 33416892 · DOI 10.1084/jem.20190086
4. Intermittent fasting for the prevention of cardiovascular disease.
   Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, et al · · 2021 · cited 66× · PMID 33512717 · DOI 10.1002/14651858.cd013496.pub2
5. Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis.
   Pellizoni FP, Leite AZ, Rodrigues NC, Ubaiz MJ, et al · · 2021 · cited 32× · PMID 33925359 · DOI 10.3390/ijerph18094621
6. Effects of dietary restriction on gut microbiota and CNS autoimmunity.
   Cantoni C, Dorsett Y, Fontana L, Zhou Y, et al · · 2022 · cited 20× · PMID 32822833 · DOI 10.1016/j.clim.2020.108575
7. Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer's Disease.
   Rahmani F, Ghezzi L, Tosti V, Liu J, et al · · 2023 · cited 15× · PMID 37005885 · DOI 10.3233/jad-221007
8. Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.
   Ghezzi L, Tosti V, Shi L, Cantoni C, et al · · 2025 · cited 11× · PMID 39137977 · DOI 10.1136/jnnp-2024-333465